Tasisulam is an anti-cancer compound that induces apoptosis through the intrinsic pathway, leading to the release of cytochrome c and caspase-dependent cell death. Additionally, tasisulam inhibits mitotic progression and triggers vascular normalization.

Tasisulam sodium, administered at concentrations ranging from 200 nM to 200 μM for a duration of 48 hours, effectively inhibits cell proliferation across various tumor types, demonstrating EC50 values of 10 μM for Calu-6 non-small cell lung carcinoma and 25 μM for A-375 melanoma cell lines. Additionally, exposure to 25 and 50 μM concentrations of Tasisulam sodium for 72 hours results in a dose-dependent increment of 4N DNA content and G2-M phase cell cycle accumulation, indicating disrupted cell cycle progression. The compound also induces apoptosis in a broad spectrum of in vitro cancer cell models when applied within the same concentration and time frame. Furthermore, Tasisulam sodium impedes the formation of endothelial cell cord structures induced by VEGF, epidermal growth factor, and fibroblast growth factor, highlighting its potential anti-angiogenic properties. These findings underscore Tasisulam sodium's multifaceted antitumor activity, encompassing antiproliferative effects, cell cycle arrest, apoptosis induction, and anti-angiogenic actions in cancer cell models[1].